Company Overview
- Website
- tolerx.com
- Phone
- (617) 354-8100
- Employees
- 9
- Founded in
- 2000
- Industry
- BioTech/Drugs
- NAICS Codes
-
32 - Manufacturing325 - Chemical Manufacturing3254 - Pharmaceutical and Medicine Manufacturing32541 - Pharmaceutical and Medicine Manufacturing
- SIC Codes
-
28 - Chemicals and Allied Products283 - Drugs2834 - Pharmaceutical Preparations
Financials & Stats
Revenue
$9B
Recent News & Media
Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
- Aug 4, 2010
- prnewswire.com
Protege Encore Study: Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
- Feb 28, 2010
- diatribe.org
Who is Tolerx
Tolerx, Inc. is a privately held company based in Cambridge, Massachusetts. With a team of 9 employees, the company focuses on developing innovative immunotherapies for a variety of conditions. Tolerx's portfolio includes a range of drug candidates targeting type 1 diabetes, autoimmune diseases, and cancer. Their lead candidate, otelixizumab, is a targeted T cell immunotherapy currently in Phase 3 development for type 1 diabetes, with GlaxoSmithKline as a partner. They also have TRX518, a targeted T cell immunotherapy in Phase 1 development for cancer, and TRX1, an anti-CD4 antibody previously clinically evaluated for treating aberrant immune responses. In addition to their clinical candidates, Tolerx has two preclinical candidates, TRX585 and TRX385, designed to enhance immune responses and are being explored for potential use in cancer and chronic viral infections. For further information, visit Tolerx's website at tolerx.com.
Tolerx Industry Tags
Tolerx Tech Stack
Companies Similar to Tolerx
Analyze industry trends and opportunities by examining competitors and companies comparable to Tolerx, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
Company Name | Revenue | Number of Employees | Location | Founded in |
---|---|---|---|---|
9M | 22 | Pittsburgh, PA | 2004 |